x

Posted 13 April, 2023

Motus GI Holdings, Inc. appointed Mark Pomeranz as new CEO

Nasdaq:MOTS appointed new Chief Executive Officer Mark Pomeranz in a 8-K filed on 13 April, 2023.


  As part of the executive changes, Mark Pomeranz, the Company's Chief Operating Officer, director and former Chief Executive Officer, has been appointed as the Company's Chief Executive Officer, effective immediately.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Motus GI Holdings, Inc.
Health Care/Life Sciences • Medical Equipment/Supplies
Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in September, 2016 and is headquartered in Fort Lauderdale, FL.
Market Cap
$1.01M
View Company Details
Motus GI Holdings, Inc. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On April 13, 2023, the Board of Directors (the "Board") of Motus GI Holdings, Inc. (the "Company") approved the implementation of certain cost cutting measures, including an executive reorganization, in connection with its ongoing efforts to reduce operating expenses. As part of the executive changes, Mark Pomeranz, the Company's Chief Operating Officer, director and former Chief Executive Officer, has been appointed as the Company's Chief Executive Officer, effective immediately. In connection with Mr. Pomeranz's appointment, Timothy Moran has stepped down as Chief Executive Officer of the Company. Mr. Moran shall succeed David Hochman as Chairman of the Board, effective immediately. Mr. Hochman will continue to serve as an independent director of the Company, effective immediately. Mr. Moran has agreed to work closely with Mr. Pomeranz to support a smooth transition and maintain key relationships with the Company's stakeholders.


Mr. Pomeranz has served as the Company's Chief Operating Officer since September 2018. Prior to his tenure as Chief Operating Officer, Mr. Pomeranz served as the Company's Chief Executive Officer from April 2014 through September 2018. Prior to joining the Company, Mr. Pomeranz was the founding Chief Executive Officer of Svelte Medical Systems, and Vice President of Research and Development at Prescient Medical, Inc. From 1998 to 2007, Mr. Pomeranz served as Vice President at Cordis, a Johnson & Johnson Company, where his responsibilities included developing new technologies, exploring new market opportunities and leading major restructuring efforts to create cross-functional global commercialization teams. Prior to that, he held a number of senior leadership roles, including positions at Cardiac Pathways Corporations from 1991 to 1998, and Cardiovascular Imaging Systems from 1989 to 1991, both of which were acquired by Boston Scientific Corporation. Mr. Pomeranz earned a M.Sc. in biomedical engineering from the University of Miami.